3042848-87-0
3042848-87-0
Chemical Structure
Risvutatug
Synonym(s): HS-20093 Antibody; GSK5764227 Antibody
- CAS No.: 3042848-87-0
- Molecular Weight:(143.94 kDa)
SMILES: [Risvutatug]
Biological Activity: Risvutatug (HS-20093 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. Risvutatug exhibits anti-tumor activity. Risvutatug can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Risvutatug | 99.57% | Risvutatug (HS-20093 Antibody) is an antibody targeting B7-H3, which can be used to synthesize the ADC HS-20093. Risvutatug exhibits anti-tumor activity. Risvutatug can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. J. Wang, et al., OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001). Volume 19, Issue 10, Supplement S17, 2024
- [2]. Lu Xie, et al., ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Journal of Clinical Oncology. 42(16), 2024
- [3]. Jie Wang, et al., ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. Journal of Clinical Oncology. 41 (16), 2023.
